Skip to main content

Table 2 Patient and tumor characteristics, overall and by histologic categories

From: Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas

 

All patients

Leiomyo-sarcomas

Undifferentiated pleomorphic sarcoma

Liposarcomas

Vascular sarcomas

Fibroblastic/myofibroblastic sarcomas

Nerve sheath sarcomas

Rhabdomyo-sarcomas

Synovial sarcomas

Others/NOS

N

4274

922

652

554

357

227

106

98

49

1309

Sex (n, %)

 Male

2103 (49.2)

307 (33.3)

390 (59.8)

329 (59.4)

195 (54.6)

122 (53.7)

64 (60.4)

43 (43.9)

28 (57.1)

625 (47.8)

 Female

2171 (50.8)

615 (66.7)

262 (40.2)

225 (40.6)

162 (45.4)

105 (46.3)

42 (39.6)

55 (56.1)

21 (42.9)

684 (52.2)

Race

 White

3729 (87.3)

783 (84.9)

576 (88.3)

499 (90.1)

309 (86.6)

203 (89.4)

96 (90.6)

82 (83.7)

43 (87.8)

1138 (86.9)

 Black

337 (7.9)

106 (11.5)

46 (7.1)

23 (4.2)

21 (5.9)

106 (8.1)

 Other

197 (4.6)

31 (3.4)

26 (4.0)

32 (5.8)

25 (7.0)

63 (4.8)

Age at advanced diagnosis

 Mean (SD)

77.8 (7.3)

76.8 (7.2)

79.4 (7.2)

77.5 (7.1)

78.2 (7.5)

77.8 (7.1)

77.7 (7.6)

76.8 (7.3)

74.1 (6.5)

78.0 (7.4)

 Median

77.4

76.1

79.7

76.6

77.9

77.8

77.3

76.6

73.5

77.5

 Min, Max

65.0, 104.1

65.0, 102.9

65.1, 99.3

65.1, 96.8

65.6, 101.8

65.7, 97.4

65.5, 95.9

65.3, 95.3

65.7, 91.0

65.1, 104.1

Pre-index date Charlson Comorbidity Index (CCI) scorea

 Mean (SD)

2.8 (2.3)

2.5 (2.2)

2.8 (2.4)

2.8 (2.3)

2.9 (2.7)

2.8 (2.2)

2.8 (2.3)

2.6 (2.1)

3.0 (2.3)

2.8 (2.4)

 Median

2.0

2.0

2.0

2.0

2.0

2.0

2.0

2.0

2.0

2.0

 Min, Max

0.0, 15.0

0.0, 14.0

0.0, 15.0

0.0, 12.0

0.0, 12.0

0.0, 11.0

0.0, 10.0

0.0, 9.0

0.0, 8.0

0.0, 15.0

Stage of disease at initial diagnosis of STS (n, %)

 Localized

1731 (40.5)

345 (37.4)

379 (58.1)

260 (46.9)

150 (42.0)

121 (53.3)

36 (34.0)

25 (25.5)

18 (36.7)

397 (30.3)

 Regional—direct extension only

938 (22.0)

200 (21.7)

135 (20.7)

177 (32.0)

62 (17.4)

59 (26.0)

32 (30.2)

14 (14.3)

11 (22.5)

248 (19.0)

 Regional—lymph nodes involved only

29 (0.7)

0 (0.0)

 Regional—direct extension and lymph nodes

37 (0.9)

0 (0.0)

 Distant

1539 (36.0)

363 (39.4)

133 (20.4)

114 (20.6)

138 (38.7)

45 (19.8)

36 (34.0)

53 (54.1)

20 (40.8)

637 (48.7)

Grade of cancer at time of initial diagnosis of STS (n, %)

 Well or moderately differentiated (grade 1 or 2)

646 (15.1)

152 (16.5)

36 (5.5)

239 (43.1)

40 (11.2)

50 (22.0)

116 (8.9)

 Poorly differentiated (grade 3)

908 (21.2)

192 (20.8)

151 (23.2)

101 (18.2)

81 (22.7)

35 (15.4)

16 (32.7)

294 (22.5)

 Undifferentiated (grade 4)

1310 (30.7)

250 (27.1)

228 (35.0)

129 (23.3)

61 (17.1)

63 (27.8)

28 (26.4)

34 (34.7)

510 (39.0)

 Unknown

1410 (33.0)

328 (35.6)

237 (36.4)

85 (15.3)

175 (49.0)

79 (34.8)

54 (50.9)

39 (39.8)

24 (49.0)

389 (29.7)

Total follow-up time (years)b

 Mean (SD)

1.7 (2.4)

1.8 (2.2)

2.0 (2.8)

2.6 (2.8)

1.1 (1.7)

2.5 (2.7)

1.4 (2.1)

0.8 (1.5)

1.4 (1.8)

1.3 (2.0)

 Median

0.7

1.0

0.8

1.5

0.5

1.6

0.5

0.3

0.6

0.5

 Min, Max

0.0, 12.8

0.0, 12.2

0.0, 12.3

0.0, 12.3

0.0, 12.5

0.0, 12.5

0.0, 9.9

0.0, 9.8

0.0, 8.8

0.0, 12.8

  1. ICD-9-CM International Classification of Diseases, 9th Revision, Clinical Modification, Max maximum, Min minimum, NOS not otherwise specified, SD standard deviation, STS soft-tissue sarcoma
  2. aBecause the objective of the CCI score was to evaluate underlying comorbidity burden independent of STS, ICD-9-CM diagnosis codes for cancer were excluded from the CCI calculation for this study
  3. bFollow-up time calculated as the number of months between the study index date (first diagnosis of advanced STS) and the earliest of death, loss of eligibility, or end of the Medicare database (December 31, 2013)